Welcome to the patients, family and friends page from the International Pediatric Multiple Sclerosis Study Group (IPMSSG)!

The International Pediatric Multiple Sclerosis Study Group is a global network of adult and pediatric neurologists, basic scientists, clinicians, representatives of MS societies and other relevant professional organisations, whose unifying vision is to optimise worldwide healthcare, education and research in pediatric multiple sclerosis and other acquired inflammatory demyelinating disorders of the central nervous system.


Our Mission is to improve the care of children with multiple sclerosis and acquired demyelinating diseases worldwide, promoting clinical initiatives, education and research.


On the website there is information about multiple sclerosis and other acquired inflammatory demyelinating disorders of the central nervous system, research, educational events and other activities.


News and Announcements

FDA approves Gilenya for children and teens with MS:


May 2018: FDA approves Gilenya for pediatric MS patients 10 years or older. Gilenya is the first FDA approved therapy for pediatric MS.

For more information, visit the Gilenya website.

Many thanks to all the families and IPMSSG members who contributed to this historic milestone!

FDA grants Gilenya Breakthrough Designation for Pediatric MS

On December 18, 2017, the FDA granted Gilenya (fingolimod) breakthrough designation for pediatric MS based on the PARADIGMS results. See these links for more details: 



Many thanks to all IPMSSG members who contributed to this historic result!


Neurology Publications on Pediatric MS


This PDF is a Parents and family summary created of recently published review articles about Pediatric MS and demyelinating disorders from the IPMSSG. The scientific versions are available on the IPMSSG Professionals website


The articles summarised in this publication are taken from a 2016 Neurology journal supplement, written by the International Pediatric MS Study Group. We gratefully acknowledge the editorial contribution of Dr Rosalind Kalb.


Associazione Italiana Sclerosi Multipla, Deutsche Multiple Sklerose Gesellschaft Bundesverband, MS Cure Fund, National MS Society (USA), Schweizerische Multiple Sklerose Gesellschaft/Société suisse de la Sclérose en plaques Scleroseforeningen, Stichting MS Research.